The verdict
Our read at a glance.
Whether exact alpha-MSH evidence supports any claim beyond endogenous peptide identity, human physiology and biomarker relevance, ex vivo or human-cell mechanisms, and preclinical plausibility.
- The signal
- This memo draws on 50 vetted references for a cautious claim-mapping read. The usable signal includes official identity records, ClinicalTrials.gov registry or biomarker records, older human physiology and disposition studies, human biomarker and prognostic studies, ex vivo immune findings, human melanocyte or keratinocyte mechanisms, exact-alpha-MSH reviews, and animal or cell mechanism papers. This is not a clinical-efficacy package.
- The unknown
- Whether exact alpha-MSH has any reproducible, product-specific clinical benefit in a defined population under modern evidence standards, and whether future records can separate exact alpha-MSH from KPV, Melanotan I, afamelanotide, Melanotan II, bremelanotide/PT-141, setmelanotide, broad melanocortin biology, and identity-uncertain market products.
- Our read
- Early human signal, low certainty. Exact alpha-MSH is source-rich enough to track, but the credible public read is cautious biology and product-identity mapping: endogenous peptide identity and mechanistic plausibility are not proof of clinical benefit or product authorization.
The mechanism
How it works.
Alpha-MSH is a small peptide the body makes by cleaving the larger POMC protein. It binds the melanocortin receptors, most visibly MC1R on skin melanocytes, where it drives melanin production and pigmentation, and it also acts at MC3R/MC4R in the brain affecting appetite and at receptors on immune cells where it dampens inflammation. These roles are established in human physiology, but that endogenous biology is not evidence that injecting exact alpha-MSH as a product produces a reliable clinical effect, and it is not interchangeable with its synthetic analogs or fragments.
Safety & regulatory boundary
The consequential part.
A source check found no current exact-alpha-MSH DailyMed finished-drug label and no clear FDA, EMA, Health Canada, or TGA finished-drug authorization for exact alpha-MSH. Alpha-MSH should not be treated as equivalent to KPV, Melanotan I, afamelanotide, Melanotan II, bremelanotide/PT-141, setmelanotide, compounded products, research-use products, internet-market products, or tanning-market products.
What's next
What we're watching.
Watch for exact-alpha-MSH regulator records, posted ClinicalTrials.gov results, peer-reviewed human intervention data with clinical outcomes, product-identity documentation, safety reporting, and reviews that keep endogenous physiology, analog evidence, fragments, and market-product claims separate.
Context
Why this is discussed.
alpha-MSH is discussed in connection with pigmentation, inflammation, metabolic, neurologic, and melanocortin-drug topics. That makes it easy to overread biology or analog evidence as support for exact-alpha-MSH products, even though analogs, fragments, labels, and market products are not interchangeable.
The evidence base
50 cited references.
Regulatory & labels1
Food and Drug Administration · Checked 2026-05-17
Registered trials4
ClinicalTrials.gov · Last updated 2015-03-25
ClinicalTrials.gov · Last updated 2024-03-05
ClinicalTrials.gov · Last updated 2022-12-22
ClinicalTrials.gov · Last updated 2026-02-06
Peer-reviewed journals4
Mauri A et al. · 1993
Song X et al. · 2009
Catania A et al. · 2000
Indexed literature (PubMed)37
Birkhauser M et al. · 1975
PubMed-indexed authors · 1978
Thody AJ et al. · 1985
Catania A et al. · 1995
Catania A et al. · 2000
Catania A et al. · 1998
Cooper A et al. · 2005
Todd SR et al. · 2009
Zierath D et al. · 2011
Feng MJ et al. · 2018
Ichiyama T et al. · 2000
Shishioh-Ikejima N et al. · 2010
Mahmoudinezhad M, Abbasalizad Farhangi M · 2021
Badawy Abdel-Naser M et al. · 2022
Thody AJ et al. · 1983
Hunt G et al. · 1994
Abdel-Malek Z et al. · 1995
Funasaka Y et al. · 1998
Zhang Y et al. · 2006
Kokot A et al. · 2009
Bohm M et al. · 2010
Bohm M, Luger TA · 2006
Millington GWM · 2010
Suzuki I et al. · 1997
Chiao H et al. · 1996
Star RA et al. · 1995
Rajora N et al. · 1996
Daynes RA et al. · 1987
Manna SK, Aggarwal BB · 1999
Taylor A, Namba K · 2001
Bettenworth D et al. · 2017
Chiao H et al. · 1997
Jo SK et al. · 2001
Deng J et al. · 2004
Varga B et al. · 2013
Sponsor & other sources4
NCBI / PubChem · Checked 2026-05-17
National Library of Medicine · 2026 descriptor page
IUPHAR/BPS Guide to Pharmacology · Current public page
NCBI / UniProtKB · Current public record
Keep reading